3T Head-Only MRI System Gets FDA Clearance
The Signa Magnus MRI device offers a slew rate and gradient amplitude that are reportedly superior to those of 60 or 70 cm bore whole-body MRI systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Signa Magnus system, a 3T magnetic resonance imaging (MRI) system for head-only scanning.
Featuring HyperG gradient technology, the Signa Magnus system facilitates faster MRI scanning with performance levels of 300 mT/m and 750 T/m/s, according to GE HealthCare, the manufacturer of the system. In addition to shorter scan times, the company said the neuroimaging system offers advanced diffusion imaging capabilities and a high signal-to-noise ratio (SNR).
GE HealthCare said the head-only emphasis of the newly FDA-cleared Signa Magnus 3T MRI system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms. (Image courtesy of GE HealthCare.)
Noting an asymmetrical design that shifts the gradient isocenter to the patient edge of the coil, GE HealthCare said the head-only emphasis of the system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms.
“We're very excited about the capabilities Signa Magnus provides,” said Kawin Setsompop, Ph.D., an associate professor of radiology at Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.”
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
